| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cardio Diagnostics Holdings Inc.$1.56
-0.06 (-3.7%)
F 7Pipeline Score Diagnostics · Clinical
Market Cap
4.76 M
EPS
-3.38
P/E Ratio
-
Value Trade
231.15 K
SEC Financials
Q1 2026Dilution Risk
Revenue
2.68 K
R&D Expenses
129.78 K
Operating CF
-1.56 M
Total Assets
9.56 M
Total Liabilities
655.97 K
Equity
8.90 M
D/E Ratio
12,345
-2.42 %
Week
-17.06 %
1 Month
-47.04 %
3 Month
-34.82 %
6 Month
-99.45 %
5 Year
-99.45 %
All Time
Cash Data
Cash Position
-
Monthly Burn
521.00 K
Runway
0 mo
Burn Trend
StableSEC Filing
May 15, 2026
Overview
Volume
22.94 K
52 Week Range
0.97 - 7.91
% held by Insiders
4.19 %
% held by Institutions
9.34 %
Enterprise Value
-1.78 M
Total Shares
2.96 M
Short %
0.17 %
Float Shares
2.69 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F7
Pipeline Score $0M
Pipeline ValueValuation Signal
1
Drugs Scored—
rNPV / MCap Top 6%
Micro Cap (rank 859 of 913)
Percentile RankCardio Diagnostics Holdings Inc. has significant pipeline risk (7/100), with 1 assets in development, but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| stent implantation Unknown | Acute Coronary Syndrome | Phase 3 | NCT01239654 | 50% | - | COMPLETED | 60 | - | - | Aug 1, 2011 | - | May 23, 2012 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CDIO
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CDIO Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
CDIO▼ -7.7%on this news
Atlas Healthcare Physicians to Cover Cardio Diagnostics’ Precision Cardiovascular Medicine Tests Across Its Network
Atlas Healthcare Physicians will cover Cardio Diagnostics' precision cardiovascular medicine tests across its network. This partnership aims to enhance patient access to advanced cardiovascular diagnostics. The collaboration is expected to improve the quality of care provided to patients within the Atlas network.
Read more →CDIO▼ -6.3%on this news· ran to +127% by day 3
Cardio Diagnostics Holdings, Inc. to Host Investor Call on Wednesday, February 18, 2026
Cardio Diagnostics Holdings, Inc. will host an investor call on February 18, 2026, to discuss its precision molecular approach to cardiovascular disease. The call will cover updates on its tests, Epi+Gen CHD™ and PrecisionCHD™, along with recent clinical data and growth initiatives. Participants can join via telephone or webcast.
Read more →CDIOLeading the Next Frontier in Precision Cardiovascular Medicine 2026 NASDAQ: CDIO 1 Certain statements and information included in this presentation constitute "forward - looking statements" within the meaning of the Priv
Cardio Diagnostics Holdings, Inc. is at the forefront of precision cardiovascular medicine, showcasing its innovative solutions powered by epigenetics and artificial intelligence. The company aims to enhance early detection and prevention of cardiovascular diseases, presenting a comprehensive growth strategy with a robust intellectual property portfolio. With a significant total addressable market and a leadership team experienced in diagnostics and AI, Cardio Diagnostics is positioned for growth amidst the ongoing challenges of cardiovascular health. The potential future impact includes not only improved patient outcomes but also a reduction in healthcare costs associated with heart diseases.
Read more →CDIO▼ -47.1%on this news
CARDIO DIAGNOSTICS HoldingS, INC. ANNOUNCES 1-for-30 reverse stock split CHICAGO, IL (Business Wire)
Cardio Diagnostics Holdings, Inc. has announced a 1-for-30 reverse stock split of its common stock, effective from May 13, 2025. This action comes as part of the company's strategy to regain compliance with Nasdaq's minimum bid price requirements. Following the split, the number of outstanding shares will decrease significantly, from approximately 52 million to about 1.7 million shares. While this move could stabilize the stock price, it also reflects underlying financial pressures within the company.
Read more →CDIO▲ +7.1%on this news
COMPANY UPDATE Revolutionizing Cardiovascular Medicine With Epigenetics and AI Certain statements and information included in this presentation constitute "forward - looking statements" within the meaning of t he Private
Cardio Diagnostics Holdings Inc. has announced key developments aimed at revolutionizing cardiovascular medicine through the integration of epigenetics and artificial intelligence. The company emphasizes the significance of forward-looking statements in their approach, highlighting a commitment to innovation within the sector. With these advancements, the company positions itself as a leader in combining cutting-edge technology with healthcare solutions.
Read more →CDIO▼ -25.9%on this news
COMPANY UPDATE Revolutionizing Cardiovascular Medicine With Epigenetics and AI MARCH 2024 Certain statements and information included in this presentation constitute "forward - looking statements" within the meaning of t
The recent company update highlights advancements in cardiovascular medicine through the integration of epigenetics and artificial intelligence. The presentation conveys a commitment to innovative medical solutions that may enhance treatment options. Additionally, forward-looking statements imply potential developments on the horizon, positioning the company favorably within the biopharma sector.
Read more →CDIOCardio Diagnostics Holdings, Inc. Regains Nasdaq Minimum Bid Price Requirement CHICAGO
Cardio Diagnostics Holdings, Inc. has announced that it has regained compliance with Nasdaq's minimum bid price requirement. Following a previous notification of non-compliance, the company successfully maintained a closing bid price of $1.00 or higher for ten consecutive business days. As a result, Nasdaq has confirmed that Cardio Diagnostics can continue its listing on the Nasdaq Capital Market, categorizing the matter as closed.
Read more →CDIO▼ -8%on this news· ran to -30% by day 3
Cardio Diagnostics Holdings, Inc Announces Financing Agreement with Yorkville Advisors Global, LP of up to $11.2 Million CHICAGO, IL
Cardio Diagnostics Holdings, Inc. has announced a financing agreement with Yorkville Advisors Global, LP for up to $11.2 million. The Company will issue convertible debentures, with the initial closing providing $4.5 million. These funds are intended to accelerate the adoption of their PrecisionCHD and Epi+Gen CHD clinical tests and support further development of new tests. The CEO highlighted the potential impact of this investment on enhancing heart disease prevention and early detection efforts.
Read more →CDIO▼ -10.4%on this news· ran to -39% by day 3
shall have the meanings ascribed to them in the Current Report on Form 8-K (the "Form 8-K")filed with the Securities and Exchange Commission (the "SEC") on
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL Capitalized terms used but not defined in this Exhibit 99.1 shall have the meanings ascribed to them in the Current Report on Form 8-K (the "Form 8-K")filed with the Securities and Exchange Commission (the "SEC") on October 31,
Read more →CDIOMana Capital Acquisition Corp. Announces Intention to Further Extend Period to Consummate Initial Business Combination Dover, DE
Mana Capital Acquisition Corp. Announces Intention Further Extend Period to Consummate Initial Business Dover, DE, September 22, 2022-Mana Capital Acquisition Corp. (Nasdaq: MAAQU; MAAQ; MAAQW; MAAQR) (the "Company" or "Mana Capital") today announced that its Board of Directo
Read more →CDIOCardio Diagnostics Announces Issuance of U.S. Patent for Compositions and Methods for Detecting Predisposition to Cardiovascular Disease CHICAGO, Ill - Cardio Diagnostics, Inc. ( Cardio Diagnostics or the Company ), a pi
Diagnostics Announces Issuance of U.S. Patent for and Methods for Detecting Predisposition to Cardiovascular Disease CHICAGO, Ill - Cardio Diagnostics, Inc. ("Cardio Diagnostics" or the "Company"), a pioneering precision cardiovascular testing company, today announced that th
Read more →CDIOTransforming Cardiovascular Cardiovascular Health Through Our AI - Driven Integrated Genetic - Epigenetic Epigenetic Engine INVESTOR PRESENTATION August 2022 MANA CAPITAL Acquisition Corp. Disclaimer General This present
Transforming Cardiovascular Cardiovascular Health Through Our AI - Driven Integrated Genetic - Epigenetic Epigenetic Engine INVESTOR PRESENTATION August 2022 MANA CAPITAL Acquisition Corp. Disclaimer General This presentation is for informational purposes and only to assist in e
Read more →CDIOMana Capital Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination Dover, DE
Mana Capital Acquisition Corp. Announces Intention Extend Period to Consummate Initial Business Combination Dover, DE, August 23, 2022-Mana Capital Acquisition Corp. (Nasdaq: MAAQU; MAAQ; MAAQW; MAAQR) (the "Company" or "Mana Capital") today announced that its Board of Direct
Read more →CDIOMana Capital Acquisition Corp. and Cardio Diagnostics, Inc. Announce Definitive Business Combination Agreement to Create Publicly Listed Company Set to Transform Cardiovascular Disease Through Epigenetics Cardio Diagnost
Capital Acquisition Corp. and Cardio Diagnostics, Inc. Definitive Business Combination Agreement to Create Listed Company Set to Transform Cardiovascular Disease Cardio Diagnostics, Inc. has pioneered a proprietary artificial intelligence-driven Integrated Genetic-Epigenetic E
Read more →CDIOMana Capital Acquisition Corp. Announces the Separate Trading of its Common Stock, Warrants and Rights, Commencing
Mana Capital Acquisition Corp. Announces the Separate Trading of its Common Stock, Warrants and Rights, Commencing Dover, DE - January 12, 2022 - Mana Capital Acquisition Corp. (Nasdaq: MAAQU) ("Mana" or the "Company"), today announced that, commencing January 14, 2022, hold
Read more →CDIOMANA CAPITAL ACQUISITION CORP. BALANCE SHEET Actual as of
MANA CAPITAL ACQUISITION CORP. Actual as of November 26, 2021 Pro Forma Adjustments As Adjusted (Unaudited) (Unaudited) ASSETS Current Assets Cash $ 887,872 $ (60,000 ) $ 827,872 Prepaid Expenses - short term 199,725 - 19
Read more →CDIOINDEX TO FINANCIAL STATEMENT Page Audited Financial Statement of Mana Capital Acquisition Corp.: Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of
Page Audited Financial Statement of Mana Capital Acquisition Corp.: Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of November 26, 2021 F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING To the Shareholders an
Read more →CDIOMana Capital Acquisition Corp. Announces Pricing of $62 Million Initial Public Offering Dover, DE
Mana Capital Acquisition Corp. Announces Pricing of $62 Million Initial Public Offering Dover, DE - November 22, 2021 - Mana Capital Acquisition Corp. ("Mana" or the "Company") today announced the pricing of its initial public offering of 6,200,000 units at a price of $10.00
Read more →Competitive Position
How CDIO ranks across every disease it competes inCompetitive Position is a premium feature
See how CDIO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial